Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 208

1.

Nurse-initiated pre-prescribed antibiotic orders to facilitate prompt and appropriate antibiotic administration in febrile neutropenia.

Walker ST, Grigg S, Kirkpatrick C, Urbancic K, Cohen E, Grigg A, Trubiano J.

Support Care Cancer. 2020 Jan 7. doi: 10.1007/s00520-019-05290-2. [Epub ahead of print]

PMID:
31912358
2.

Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals.

Chua CC, Grigg A, Singh J, Droogleever MP, Zhang L, Lim A, Fong CY, Ting SB, Schwarer A, Tiong IS, Wei AH.

Leuk Lymphoma. 2020 Apr;61(4):848-854. doi: 10.1080/10428194.2019.1691192. Epub 2019 Nov 21.

PMID:
31752581
3.

A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML.

Schwarer AP, Butler J, Jackson K, Beligaswatte A, Martin L, Kennedy G, Daniela Z, Lewis I, Hiwase D, Wight J, He S, Grigg A, Morris K, Mollee P, Marlton P.

Hemasphere. 2018 Nov 28;2(6):e158. doi: 10.1097/HS9.0000000000000158. eCollection 2018 Dec.

4.

Atypical Sarcoid-like Granulomatous Reactions in Lymphoma: Natural History and Effect on Management.

Ramanan R, Fancourt T, Berlangieri S, Grigg A.

Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):e11-e14. doi: 10.1016/j.clml.2019.10.005. Epub 2019 Oct 16. No abstract available.

PMID:
31699656
5.

Management of Patients With Erythropoietic Protoporphyria-Related Progressive Liver Disease.

Ardalan ZS, Chandran S, Vasudevan A, Angus PW, Grigg A, He S, Macdonald GA, Strasser SI, Tate CJ, Kennedy GA, Testro AG, Gow PJ.

Liver Transpl. 2019 Nov;25(11):1620-1633. doi: 10.1002/lt.25632. Epub 2019 Sep 30.

PMID:
31469227
6.

New advances in the management of cytomegalovirus in allogeneic haemopoietic stem cell transplantation.

Yong MK, Gottlieb D, Lindsay J, Kok J, Rawlinson W, Slavin M, Ritchie D, Bajel A, Grigg A.

Intern Med J. 2020 Mar;50(3):277-284. doi: 10.1111/imj.14462. Review.

PMID:
31403736
7.

Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia.

Sellar RS, Mehra V, Fox TA, Grigg A, Kulasekararaj A, Sarma A, de Lavallade H, McLornan D, Raj K, Mufti GJ, Pagliuca A, Mackinnon S, Chakraverty R, Fielding AK, Carpenter B, Kottaridis PD, Khwaja A, Peggs KS, Thomson KJ, Morris EC, Potter VT.

Br J Haematol. 2019 Oct;187(1):e20-e24. doi: 10.1111/bjh.16136. Epub 2019 Aug 8. No abstract available.

PMID:
31396948
8.

Nivolumab induces dynamic alterations in CD8 T-cell function and TIM-3 expression when used to treat relapsed acute myeloid leukemia after allogeneic stem cell transplantation.

Wong E, Davis J, Koldej R, Szer J, Grigg A, Ritchie D.

Leuk Lymphoma. 2020 Jan;61(1):185-188. doi: 10.1080/10428194.2019.1648803. Epub 2019 Aug 7. No abstract available.

PMID:
31389281
9.

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.

Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, Gaidano G, Lee JJ, Abhyankar S, Solano C, Perez de Oteyza J, Satlin MJ, Schwartz S, Campins M, Rocci A, Vallejo Llamas C, Lee DG, Tan SM, Johnston AM, Grigg A, Boeckh MJ, Campora L, Lopez-Fauqued M, Heineman TC, Stadtmauer EA, Sullivan KM; ZOE-HSCT Study Group Collaborators.

JAMA. 2019 Jul 9;322(2):123-133. doi: 10.1001/jama.2019.9053. Erratum in: JAMA. 2019 Aug 27;322(8):785.

10.

Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents.

Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K.

Clin Liver Dis. 2019 Aug;23(3):521-534. doi: 10.1016/j.cld.2019.04.012. Epub 2019 Jun 5. Review.

PMID:
31266625
11.

Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies.

Sasadeusz J, Grigg A, Hughes PD, Lim SL, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K.

Clin Liver Dis. 2019 Aug;23(3):511-519. doi: 10.1016/j.cld.2019.04.011. Epub 2019 Jun 6. Review.

PMID:
31266624
12.

Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant Recipients.

Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K.

Clin Liver Dis. 2019 Aug;23(3):493-509. doi: 10.1016/j.cld.2019.04.010. Epub 2019 Jun 6. Review.

PMID:
31266623
13.

Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology.

Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K.

Clin Liver Dis. 2019 Aug;23(3):487-492. doi: 10.1016/j.cld.2019.04.009. Epub 2019 Jun 6. Review.

PMID:
31266622
14.

Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations.

Ong DM, Ashby M, Grigg A, Gard G, Ng ZY, Huang HE, Chong YS, Cheah CY, Devitt B, Chong G, Loh Z, Mo A, Hawkes EA.

Br J Haematol. 2019 Oct;187(1):73-81. doi: 10.1111/bjh.16049. Epub 2019 Jun 17.

PMID:
31206608
15.

Functional Antibody Responses Following Allogeneic Stem Cell Transplantation for TP53 Mutant pre-B-ALL in a Patient With X-Linked Agammaglobulinemia.

van Zelm MC, Pumar M, Shuttleworth P, Aui PM, Smart JM, Grigg A, Bosco JJ.

Front Immunol. 2019 Apr 26;10:895. doi: 10.3389/fimmu.2019.00895. eCollection 2019.

16.

The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia.

Minson AG, Cummins K, Fox L, Costello B, Yeung D, Cleary R, Forsyth C, Tatarczuch M, Burbury K, Motorna O, Shortt J, Fleming S, McQuillan A, Schwarer A, Harrup R, Holmes A, Ratnasingam S, Chan KL, Hsu WH, Ashraf A, Putt F, Grigg A.

Blood Adv. 2019 Apr 9;3(7):1084-1091. doi: 10.1182/bloodadvances.2018028035.

17.

Is there a role for proton pump inhibitor prophylaxis in haematology patients?

Leitinger E, Hui L, Grigg A.

Intern Med J. 2019 Jun;49(6):694-701. doi: 10.1111/imj.14241. Review.

PMID:
30719802
18.

The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia.

Lasica M, Willcox A, Burbury K, Ross DM, Branford S, Butler J, Filshie R, Januszewicz H, Joske D, Mills A, Simpson D, Tam C, Taylor K, Watson AM, Wolf M, Grigg A.

Leuk Lymphoma. 2019 Jul;60(7):1796-1802. doi: 10.1080/10428194.2018.1551533. Epub 2019 Jan 11.

PMID:
30632843
19.

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.

Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, Rodig SJ, Ligon AH, Roemer MGM, Reddy N, Cohen JB, Assouline S, Poon M, Sharma M, Kato K, Samakoglu S, Sumbul A, Grigg A.

J Clin Oncol. 2019 Feb 20;37(6):481-489. doi: 10.1200/JCO.18.00766. Epub 2019 Jan 8.

20.

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W.

Haematologica. 2019 Jun;104(6):1202-1208. doi: 10.3324/haematol.2018.209015. Epub 2018 Dec 20.

Supplemental Content

Loading ...
Support Center